AKT2 and cancer: Lastly, aside from the AKT1-specific inhibitor A-674563 and the AKT2-specific inhibitor CCT128930 (both ATP-competitive inhibitors), most AKT inhibitors lack isoform specificity, and isoform-specific treatments should be tailored to the cancer in question for reasons mentioned above.